Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

277 articles with Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

• Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

  5/18/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 10,596,027 Units at a purchase price of $0.755.

• Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

  3/31/2022

  Tenax Therapeutics, Inc. today reported financial results for the year ended December 31, 2021 and provided a business update.

• Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

  3/30/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), today announced that two presentations will be made at the upcoming American College of Cardiology (ACC) Scientific Sessions featuring the Company’s lead drug candidates, imatinib and levosimendan.

• 

  BioSpace Movers & Shakers, Feb. 4

  2/4/2022

  Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

• Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

  1/31/2022

  Tenax Therapeutics, Inc. announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022.

• Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

  1/12/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company’s subcutaneous formulation of levosimendan.

• Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

  1/4/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), today provided patent and clinical program updates for its two lead product candidates, TNX-103 for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF), and TNX-201 for the treatment of pulmonary arterial hypertension (PAH).

• Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

  11/16/2021

  Tenax Therapeutics, Inc. today reported financial results for the third quarter of 2021 and provided a business update.

• Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

  10/6/2021

  Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib.

• Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

  9/28/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview at the virtual Benziga Healthcare Small Cap Conference being held from September 29-30, 2021.

• Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference.

• Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

  8/17/2021

  Tenax Therapeutics, Inc. today reported financial results for the second quarter of 2021 and provided a business update.

• Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

  8/12/2021

  Tenax Therapeutics, Inc. today announced a new publication that identifies a novel mechanism of action behind the improved cardiovascular hemodynamics and exercise tolerance that was reported in the recent Phase 2 HELP Study (Burkhoff et al., JACC Heart Failure 2021; 9:360-70).

• Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  8/5/2021

  Tenax Therapeutics, Inc. announced that it will hold a KOL webinar on Levosimendan for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The webinar will be held on August 16, 2021 at 10:00am Eastern Time.

• 

  New CEOs Named at Two Biopharma Companies

  7/8/2021

  Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.

• Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

  7/7/2021

  Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

• Tenax Therapeutics Set to Join Russell Microcap® Index

  6/10/2021

  Tenax Therapeutics Set to Join Russell Microcap ® Index.

• Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

  5/17/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update.

• Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

  4/9/2021

  Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

• Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders

  4/7/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors of Tenax Therapeutic